OSE Immunotherapeutics Updates on Anti-IL-7 Receptor Antagonist OSE-127/S95011, a Breakthrough Approach in Chronic Inflammatory Autoimmune Diseases an
OSE Immunotherapeutics Updates on Anti-IL-7 Receptor Antagonist OSE-127/S95011, a Breakthrough Approach in Chronic Inflammatory Autoimmune Diseases and Hematology·        Positive Phase 1 clinical results published in 'The Journal of Immunology’ (online)· &...
United States Olmsted County University Medical Center United Kingdom Nicolas Poirier Xenografts Pdxs
Source: pharmiweb.com